Artiva Biotherapeutics initiated with a Buy at TD Cowen

TD Cowen analyst Tyler Van Buren initiated coverage of Artiva Biotherapeutics with a Buy rating and no price target. The firm says many cell therapy players are entering the autoimmune space but that Artiva’s approach is unique. The company’s AlloNK has demonstrated “impressive efficacy” and safety in non-Hodgkin lymphoma, which should translate to success in autoimmune indications, the analyst tells investors in a research note.